According to Zhitong Finance APP, on September 1, 2025, IVD MEDICAL (01931) announced the acquisition of 20.31% equity in Guofu Quantum (00290) for HKD 3.142 billion, becoming the controlling shareholder of this quantum technology company that holds Hong Kong financial licenses 1, 4, 6, and 9.
This transaction is not only a capital operation but also a key step for IVD MEDICAL in building a global RWA tokenized digital trading platform. Through this acquisition, IVD MEDICAL gains Guofu Quantum's expertise and financial license resources in the digital asset and RWA fields, injecting strong momentum into its RWA exchange ecosystem.
<h2>1. Transaction Details: A HKD 3.1 Billion Acquisition</h2>
According to the sale and purchase agreement, a wholly-owned subsidiary of IVD MEDICAL will issue and allot approximately 324 million consideration shares at a price of about HKD 9.69 per share to acquire 20.31% equity in Guofu Quantum. Upon completion of the transaction, IVD MEDICAL will hold 20.31% of Guofu Quantum's shares, becoming its controlling shareholder.
<img src="https://imageproxy.pbkrs.com/https://img.zhitongcaijing.com/image/20250901/1756690887843958.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="image.png" original-src="https://imageproxy.pbkrs.com/https://img.zhitongcaijing.com/image/20250901/1756690887843958.png"/>
Announcement from IVD MEDICAL on September 1
This acquisition represents a high degree of strategic synergy between the two companies.
IVD MEDICAL was originally a medical testing equipment distribution company, and since July 2025, its stock price has performed actively, with a cumulative increase of nearly 480% over two months, and its market value once exceeding HKD 16 billion. This change is attributed to the company's proactive promotion of its blockchain strategy, building the world's first innovative drug intellectual property RWA exchange, ivd.xyz. This platform adopts the &#34;NewCo+RWA+stablecoin&#34; model, aiming to tokenize high-value medical assets (such as ADC drugs, gene therapy patents, etc.) to address pain points such as insufficient liquidity and long financing cycles in the medical industry.
In August, IVD MEDICAL further advanced its &#34;Global Enhanced Ethereum (ETH) Treasury&#34; strategy, completing the first batch of compliant purchases of HKD 149 million in ETH in cooperation with HashKey Exchange, and seeking shareholder approval for a HKD 3 billion ETH purchase authorization, aiming to position the company's ETH reserves and per-share ETH quantity as leading in the Hong Kong stock market and globally.
Guofu Quantum, as a cross-border and cross-industry technology innovation investment platform, not only holds multiple financial licenses in Hong Kong but also possesses qualifications for QFI, CIBM, QDIE, and has built an ecological closed loop of &#34;science and technology + finance + art + trade.&#34; In recent years, the company has actively laid out in the quantum technology and RWA fields, strategically investing in Shenzhen Luanxuan Technology, acquiring equity in Huake Intelligent, and promoting RWA-related cooperation and financing multiple times in 2025, strengthening its layout in digital asset issuance, pre-RWA, and secondary market funds.
For IVD MEDICAL, this acquisition enables it to gain Guofu Quantum's expertise and resources in the digital asset and RWA fields, injecting strong momentum into its RWA exchange ecosystem
<h2>II. Strategic Synergy: Creating the &#34;Alibaba&#34; of the RWA Space</h2>
The strategic significance of Huajian Medical's acquisition of Guofu Quantum is self-evident. On one hand, Huajian Medical has gained financial license resources and professional capabilities in the digital asset field from Guofu Quantum; on the other hand, Guofu Quantum has received financial support and medical industry resources from Huajian Medical.
This synergy helps both parties jointly create a complete ecological closed loop for the tokenization of medical innovative drug intellectual property and the tokenization of high-tech assets of global listed companies.
Huajian Medical's RWA exchange provides a technical platform and trading venue for asset tokenization, while Guofu Quantum offers financial license resources, digital asset issuance and trading capabilities, as well as professional technical support in the field of quantum technology.
This combination is somewhat akin to Alibaba (09988) connecting countless small and medium-sized enterprises with the global market back in the day. This acquisition by Huajian Medical of Guofu Quantum aims to create an RWA exchange that connects trillions of real assets globally with global capital, potentially becoming the most dominant platform giant in this sector.
Medical innovative drug assets are characterized by high value, long R&amp;D cycles, and poor liquidity, making them very suitable for improving liquidity and reducing financing costs through RWA tokenization.
According to the Pharmaceutical Cube report, the total transaction amount of related innovative drugs in China for the first half of 2025 is projected to be USD 60.8 billion, which is USD 3.7 billion higher than the total transaction amount for the entire year of 2024, representing a year-on-year growth of 129%.
This indicates that the assets of domestic innovative drug companies are being widely recognized in the global market, and China's position in the global innovative drug trading market is becoming increasingly prominent.
<h2>III. Policy Tailwind: Synchronization of Innovative Drug Going Global and Digital Asset Regulation</h2>
The strategic layout of Huajian Medical and Guofu Quantum aligns perfectly with national policy directions. The National Healthcare Security Administration and the National Health Commission jointly issued &#34;Several Measures to Support the High-Quality Development of Innovative Drugs,&#34; clearly stating the goal of &#34;promoting the development of the global market for innovative drugs.&#34;
The policy encourages the establishment of a global innovative drug trading platform and supports innovative drug companies in leveraging the advantages of Hong Kong and Macau to promote industry expansion overseas. This provides policy support for the innovative drug trading platform constructed by Huajian Medical.
At the same time, Hong Kong has also made significant progress in digital asset regulation. On August 1, 2025, Hong Kong's &#34;Stablecoin Ordinance&#34; officially came into effect, establishing a licensing system for fiat stablecoin issuers.
This ordinance provides clear regulatory basis for the token issuance and trading segments in RWA business, further reducing compliance risks.
The United States has also made important strides in digital asset regulation. On July 18, 2025, U.S. President Trump signed the &#34;Guidance and Establishment of the U.S. National Stablecoin Innovation Act&#34; (referred to as the &#34;Genius Act&#34;), marking the first formal establishment of a regulatory framework for digital stablecoins in the U.S.
The clarification of these regulatory policies provides institutional guarantees for the development of RWA business and creates a favorable external environment for the strategic layout of Huajian Medical and Guofu Quantum.
<h2>IV. Challenges Remain, Liquidity and Regulation are Key</h2>
Despite the broad prospects, RWA still faces challenges such as liquidity dilemmas, regulatory complexities, and product mechanism defects. The tokenization of non-financial assets faces issues such as insufficient order book depth and low liquidity. On the regulatory front, the classification of assets as securities varies across different jurisdictions, complicating compliance processes
In addition, existing tokenized products such as xStocks exhibit a phenomenon of decoupling from the prices of real assets, and the mechanism is still not perfect.
<h2>V. Outlook: A Bridge Connecting Traditional Finance and Web3</h2>
Despite the challenges, the development prospects of RWA remain broad. According to the &#34;RWA Industry Development Research Report&#34; released by the Hong Kong Web3.0 Standardization Association, the RWA industry is at a critical juncture of transitioning from proof of concept to large-scale application.
By June 2025, the total locked value (TVL) of RWA is expected to reach $12.5 billion, an increase of 124% compared to 2024. In just the first half of 2025, the market size surged from $8.6 billion to over $23 billion, an increase of over 260%.
The collaboration between IVD MEDICAL and Guofu Quantum is expected to promote the tokenization process of medical and other high-tech assets, activating trillions of dormant assets and building an efficient platform connecting real assets with global capital. If successful, IVD MEDICAL is expected to become the &#34;Alibaba&#34; in the RWA field, leading a new industry ecosystem

01931

IVD MEDICAL acquired a 20.31% stake in Guofu Quantum for HKD 3.142 billion, becoming the controlling shareholder and promoting the RWA tokenization market. This transaction will enhance IVD MEDICAL's capabilities in the digital asset field and assist in building a global RWA trading platform. IVD MEDICAL's stock price has risen nearly 480% in two months, with a market capitalization exceeding HKD 16 billion, actively advancing its blockchain strategy and committed to addressing the liquidity issues in the healthcare industry

- On September 1, 2025, Huajian Medical announced the acquisition of a 20.31% stake in Guofu Quantum for HKD 3.142 billion, becoming its controlling shareholder.  
- This strategic move aims to enhance Huajian's capabilities in digital assets and RWA tokenization, facilitating the development of a global RWA trading platform.  
- The acquisition aligns with national policies promoting innovation in pharmaceuticals and digital asset regulation, positioning Huajian to potentially dominate the RWA market.

The "Alibaba" of the RWA world is born? IVD MEDICAL acquires Guofu Quantum to activate trillions of dormant assets